Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Bicara Therapeutics Inc.

Bicara Therapeutics Inc. (BCAX)

Market is closed
News
  • Displaying 2
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors.

Keep Reading →

May 27th, 2025 - News

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

The company's abstract provided a number of encouraging results for HPV-negative patients.

Keep Reading →

May 26th, 2025 - News

Insider Monkey Quarterly Strategy
+373.4% Insider Monkey Quarterly Strategy
+154.9% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
300%
200%
100%
Subscribe Now

Returns since its inception in May 2014 (through February 19th, 2025)